Diurnal Group PLC | Income Statement

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
6.00
6.00
6.50
6.00
7.00
15
Gross Income
6.00
6.00
6.50
6.00
7.00
58
SG&A Expense
1,209.00
1,592.00
2,972.30
6,363.00
12,067.00
16,837
EBIT
1,215.00
1,598.00
2,978.80
6,369.00
12,074.00
16,779
Unusual Expense
-
12.00
6.00
623.00
-
-
Non Operating Income/Expense
336.00
661.00
222.90
-
9.00
-
Interest Expense
3.00
57.00
32.30
133.00
272.00
221
Pretax Income
881.00
981.00
2,786.80
7,062.00
12,155.00
16,905
Income Tax
20.00
97.00
74.80
491.00
2,730.00
2,282
Consolidated Net Income
861.00
884.00
2,712.00
6,571.00
9,425.00
14,623
Net Income
861.00
884.00
2,712.00
6,571.00
9,425.00
14,623
Net Income After Extraordinaries
861.00
884.00
2,712.00
6,571.00
9,425.00
14,623
Net Income Available to Common
861.00
884.00
2,712.00
6,571.00
9,425.00
14,623
EPS (Basic)
23.82
24.05
50.65
0.15
0.18
0.27
Basic Shares Outstanding
52,210.80
52,210.80
52,210.80
43,746.00
52,235.00
55,119
EPS (Diluted)
0.02
0.02
0.05
0.15
0.18
0.27
Diluted Shares Outstanding
52,210.80
52,210.80
52,210.80
43,746.00
52,235.00
55,119
EBITDA
1,209.00
1,592.00
2,972.30
6,363.00
12,067.00
16,765
Non-Operating Interest Income
1.00
1.00
7.40
63.00
182.00
95

About Diurnal Group

View Profile
Address
Cardiff Medicentre
Cardiff South Glamorgan CF14 4UJ
United Kingdom
Employees -
Website http://diurnal.co.uk
Updated 07/08/2019
Diurnal Group Plc is a specialty pharmaceutical company which addresses the unmet clinical and patient needs for hormone replacement treatments by creating products for life-long treatment for the chronic conditions, which include adrenal insufficiency, rheumatoid arthritis, hypogonadism and hypothryroidism. Its hormone therapeutics is used for proprietary formulations and novel physiological treatment regimes of approved drugs. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom.